作者：李丽，赵文萍

单位：

071000 河北省保定市，河北大学附属医院心脏中心；通信作者：赵文萍，E-mail：heartfailure1@sina.com

关键词：

心血管疾病；心力衰竭；射血分数降低的心力衰竭；沙库巴曲缬沙坦；综述

Keywords：

Cardiovascular diseases；Heart failure；Heart failure with reduced ejection fraction；Sacubitri/valsartan；Review

CLC：

R 541.6

DOI：

DOI：10.3969/j.issn.1008-5971.2020.05.017

Funds：

摘要：

近年来，多项研究表明沙库巴曲缬沙坦治疗射血分数降低的心力衰竭（HFrEF）效果优于传统药物血管紧张素转换酶抑制剂（ACEI）/ 血管紧张素Ⅱ受体阻滞剂（ARB）。2019 年欧洲心脏病学会专家共识会议报告指出，沙库巴曲缬沙坦可作为新发 HFrEF 或失代偿性心力衰竭〔左心室射血分数（LVEF）<40%〕住院或门诊患者的起始治疗方案。本文综述沙库巴曲缬沙坦在多种心血管疾病如HFrEF、射血分数中间值的心力衰竭、射血分数保留的心力衰竭、急性失代偿性心力衰竭、急性心肌梗死、高血压、慢性肾脏病、糖尿病、儿童心力衰竭中的研究进展，并分析其安全性和不良反应，同时指出未来研究方向。

Abstract：

In recent years，several important studies in the field of heart failure with reduced ejection fraction（HFrEF） have shown that sacubitril/valsartan is superior to traditional drugs angiotensin-converting enzyme inhibitors （ACEI）/angiotensin Ⅱ blockers（ARB）.An expert consensus meeting report of the heart failure association of the european society ofcardiology reports that initiation of sacubitril/valsartan may be considered for patients hospitalized with new-onset heart failureor decompensated chronic heart failure （LVEF<40%）.This article reviewed the additional cardiovascular protective effectsof sacubitril/valsartan，such as HFrEF，heart failure with mid-range ejection fraction，heart failure with preserved ejectionfraction，acute decompensated heart failure，heart failure after acute myocardial infarction，hypertension，chronic kidneydisease，diabetes，and paediatric heart failure.We will analyze their safety，adverse reactions，and point out future researchdirections.

ReferenceList：